SCYNEXIS, Inc. (SCYX) Shares Up -2%
Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) were up 2% during trading on Thursday . The company traded as high as $2.48 and last traded at $2.39. 261,032 shares were traded during mid-day trading, an increase of 2% from the average session volume of 256,166 shares. The stock had previously closed at $2.44.
Several equities analysts have commented on SCYX shares. Aegis reissued a “buy” rating on shares of SCYNEXIS in a research report on Tuesday, May 30th. Zacks Investment Research lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. ValuEngine raised SCYNEXIS from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Roth Capital started coverage on SCYNEXIS in a research report on Monday, July 10th. They set a “buy” rating and a $8.50 price objective for the company. Finally, HC Wainwright set a $14.00 price objective on SCYNEXIS and gave the company a “buy” rating in a research report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.25.
The company’s 50-day moving average is $1.84 and its 200 day moving average is $2.08. The stock’s market capitalization is $61.73 million.
Hedge funds have recently modified their holdings of the business. Iguana Healthcare Management LLC lifted its holdings in shares of SCYNEXIS by 20.0% in the 1st quarter. Iguana Healthcare Management LLC now owns 300,000 shares of the company’s stock worth $828,000 after buying an additional 50,000 shares during the period. Federated Investors Inc. PA lifted its holdings in shares of SCYNEXIS by 23.5% in the 2nd quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock worth $7,533,000 after buying an additional 800,040 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of SCYNEXIS by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares during the period. KCG Holdings Inc. purchased a new stake in shares of SCYNEXIS in the 1st quarter worth $416,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of SCYNEXIS in the 1st quarter worth $154,000. Institutional investors and hedge funds own 36.75% of the company’s stock.
WARNING: “SCYNEXIS, Inc. (SCYX) Shares Up -2%” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/23/scynexis-inc-scyx-shares-up-2.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.